Cycle control and side effects of a new combiphasic oral contraceptive regimen.
In a multicentre study 882 women were treated during a total of 12,850 cycles with a new combiphasic contraceptive: CTR 24. The study period was 18 cycles. The combiphasic preparation CTR 24 contains 25 micrograms desogestrel (CAS 54024-22-5) plus 40 micrograms ethinylestradiol (CAS 57-63-6) daily for the first 7 days followed by the combination of 125 micrograms desogestrel and 30 micrograms ethinyl-estradiol daily for the subsequent 15 days. The bleeding patterns were analysed over pill cycles and a comparison was made between starters and switchers. The cycle control of the combination was very good. The side effect profile was favourable.
Dieben
T O
TO
N.V. Organon, Oss, The Netherlands.
op ten Berg
M T
MT
Coelingh Bennink
H J
HJ
D000328:Adult; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000494:pharmacology; D017135:Desogestrel / Q000009:adverse effects / Q000494:pharmacology*; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects*; D008598:Menstruation / Q000187:drug effects; D008599:Menstruation Disturbances / Q000139:chemically induced
D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D004997:Ethinyl Estradiol; C034653:Oviol; D017135:Desogestrel